TY - JOUR
T1 - Follicular Lymphoma
T2 - Past, Present, and Future
AU - Becnel, Melody R.
AU - Nastoupil, Loretta J.
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Even in the modern era, follicular lymphoma (FL) remains largely an incurable but treatable disease with both standard and novel treatment modalities. Despite the abundance of efficacious treatment modalities currently available, there is no universally agreed upon standard approach to treatment for patients with FL, particularly in the relapsed/refractory (R/R) setting. There is an increasing need for better tools to risk-stratify patients and to identify those likely to experience relapse early. Additionally, the use of gene expression profiling and next-generation sequencing techniques in recent years has led to a wealth of knowledge regarding the molecular drivers of lymphomagenesis; however, much of this knowledge is not currently applicable on a day to day basis in the clinic setting. Further studies are needed to determine a validated, clinically relevant predictive model that incorporates patient factors and molecular factors that will guide clinicians on the most effective treatment strategy. With many questions left unanswered, it is our opinion that the treatment of FL and sequencing of therapy in the R/R setting should be a personalized approach that balances patient-specific factors such as preferences and comorbidities with treatment-related factors such as known response rates and toxicity profiles.
AB - Even in the modern era, follicular lymphoma (FL) remains largely an incurable but treatable disease with both standard and novel treatment modalities. Despite the abundance of efficacious treatment modalities currently available, there is no universally agreed upon standard approach to treatment for patients with FL, particularly in the relapsed/refractory (R/R) setting. There is an increasing need for better tools to risk-stratify patients and to identify those likely to experience relapse early. Additionally, the use of gene expression profiling and next-generation sequencing techniques in recent years has led to a wealth of knowledge regarding the molecular drivers of lymphomagenesis; however, much of this knowledge is not currently applicable on a day to day basis in the clinic setting. Further studies are needed to determine a validated, clinically relevant predictive model that incorporates patient factors and molecular factors that will guide clinicians on the most effective treatment strategy. With many questions left unanswered, it is our opinion that the treatment of FL and sequencing of therapy in the R/R setting should be a personalized approach that balances patient-specific factors such as preferences and comorbidities with treatment-related factors such as known response rates and toxicity profiles.
KW - Follicular lymphoma treatment
KW - Indolent lymphoma
KW - Non-Hodgkin lymphoma
KW - Novel therapy in follicular lymphoma
KW - Sequencing therapy in follicular lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85047666001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047666001&partnerID=8YFLogxK
U2 - 10.1007/s11864-018-0550-0
DO - 10.1007/s11864-018-0550-0
M3 - Review article
C2 - 29796824
AN - SCOPUS:85047666001
SN - 1527-2729
VL - 19
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 7
M1 - 32
ER -